Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Gross Profit: 2016-2024

Historic Gross Profit for Summit Therapeutics (SMMT) over the last 5 years, with Dec 2024 value amounting to -$9,000.

  • Summit Therapeutics' Gross Profit was N/A to -$9,000 in Q4 2024 from the same period last year, while for Dec 2024 it was -$8.7 million, marking a year-over-year change of. This contributed to the annual value of -$8.7 million for FY2024, which is 43.82% up from last year.
  • Per Summit Therapeutics' latest filing, its Gross Profit stood at -$9,000 for Q4 2024, which was up 99.63% from -$2.5 million recorded in Q3 2024.
  • Over the past 5 years, Summit Therapeutics' Gross Profit peaked at $324,312 during Q1 2020, and registered a low of -$3.1 million during Q1 2024.
  • Over the past 2 years, Summit Therapeutics' median Gross Profit value was -$2.5 million (recorded in 2024), while the average stood at -$1.7 million.
  • Data for Summit Therapeutics' Gross Profit shows a maximum YoY crashed of 33.57% (in 2020) over the last 5 years.
  • Quarterly analysis of 3 years shows Summit Therapeutics' Gross Profit stood at $324,312 in 2020, then followed by $220,000 in 2022, then followed by -$9,000 in 2024.
  • Its Gross Profit was -$9,000 in Q4 2024, compared to -$2.5 million in Q3 2024 and -$3.1 million in Q2 2024.